Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.61 |
| ▸ | NPY1R | P25929 | 9/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.61 |
| ▸ | NPY2R | P49146 | 5/20 | 0.61 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30589456 | 1.00 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL29461983 | 1.00 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL30309304 | 0.97 | NPY4R (0.65) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL22117539 | 0.96 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL22117541 | 0.96 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL29531737 | 0.92 | NPY4R (0.51) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL31680267 | 0.92 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL29641047 | 0.91 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30341658 | 0.91 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30449937 | 0.91 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260061023-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-03-05 | — | — | US | disclosed |
| US-12268724-B2 | Methods and compositions for the prevention or treatment of Barth Syndrome | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240156892-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-11771734-B2 | Methods and compositions for the prevention or treatment of Barth syndrome | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260061023-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME | ARG2, ARGLU1, BCAT1 | NPY4R 2600/4885NPY1R 872/4885NPY5R 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.